Oct 5 Eli Lilly Co said on Wednesday it
would buy German drugmaker Boehringer Ingelheim's U.S. pet
vaccines business and a manufacturing plant for $885 million.
Lilly's Elanco animal health company will get Boehringer's
U.S. feline, canine and rabies vaccines portfolio, as well as
several experimental products.
Indianapolis-based Lilly will gain access to BI's Fort
Dodge, Iowa-based plant, which is used for vaccine manufacturing
as well as research and development.
Elanco, whose U.S. offerings include parasiticides, pain and
dermatology medicines, said the deal would add to its adjusted
earnings in 2018.
The transaction is expected to close by early 2017, the
The deal is contingent on antitrust approval as well as the
closing of an asset swap between BI and France's Sanofi SA
, signed in June.
Jefferies is Lilly's financial adviser and Paul Hastings LLP
and Paul, Weiss, Rifkind, Wharton & Garrison LLP are its legal
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by